Celadon this week begins life as a listed company; the first company to be admitted to the London Stock Exchange AIM Market since the legalisation of cannabis-based medicinal products in 2018, and the first since GW Pharma.
Governed by the UK regulators and trials underway targeting MHRA approval, we have ambitious plans to advance the understanding and regulation of high-quality, medicinal cannabinoid-based medicines.
It has been a huge achievement to get this far and we are enormously grateful to our staff, our investors and our partners Cannacord Genuity Group, CMS, RMS and Tessera.
Recent Comments